Mikołaj Słabicki, PhD
Mikołaj Słabicki earned his Ph.D. at the Max Planck Institute of Molecular Cell Biology and Genetics in Dresden, Germany. Dr. Słabicki then conducted his post-doctoral research as a Marie Skłodowska Curie Scholar in Dr. Benjamin Ebert’s laboratory at the Dana-Farber Cancer Institute and in Stefan Fröhling’s laboratory at the German Cancer Research Center in Heidelberg, Germany. Mikołaj Słabicki later became a Group Leader in the Cancer Program at the Broad Institute, a member of Dr. Benjamin Ebert’s Laboratory, and a Senior Staff Scientist at the Dana-Farber Cancer Institute. In the summer of 2024, Mikołaj began a faculty position at the Massachusetts General Hospital (MGH) Cancer Center. His laboratory aims to expand the druggable proteome by employing functional genomics, high-throughput screening, chemical biology, cell biology, and biochemical techniques to identify and characterize new molecular glue degraders and novel mechanisms of targeted protein degradation.